Stelios Papadopoulos has been involved with the biotech and pharma industries for nearly three decades. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in August 2006 after six years with the firm where, as an investment banker, he focused on the biotech and pharma sectors. Prior to joining Cowen, he spent thirteen years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in April 1987 from Drexel Burnham Lambert where he was a Vice President in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was a biotechnology analyst at Donaldson, Lufkin & Jenrette.
Before coming to Wall Street, Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with NYU Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds an MS in Physics, a PhD in biophysics and an MBA in finance, all from New York University.
Stelios Papadopoulos is a co-founder and chairman of the Board of Directors of both, Exelixis, Inc., and Anadys Pharmaceuticals, Inc.; he is a co-founder and a member of the Board of Directors of Cellzome, Inc. He is a member of the Board of Directors of Biogen Idec, Inc., BG Medicine, Inc., Joule Unlimited, Inc. and Regulus Therapeutics, Inc. In the not-for-profit sector, Papadopoulos is a co-founder and Chairman of Fondation Santé, a member of the Board of Visitors of Duke University Medical Center, and a member of the Board of Directors of the National Marrow Donor Program (NMDP).
September 11, 2019
© 2007-2019, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.